Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veritas In SilicoTSE:130A -2.26%28 Current Ratio is 16.46 as of Jun. 2026, which is 40% below its 10-year median of 27.64. GuruFocus rates TSE:130A with a GF Score™ of 28/100 and a GF Value™ of 円266.95 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Veritas In Silico ranks better than 89.43% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Veritas In Silico's current ratio for the quarter that ended in Jun. 2026 was 16.46.
Veritas In Silico has a current ratio of 16.46. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Veritas In Silico's Current Ratio or its related term are showing as below:
TSE:130A'
s Current Ratio Range Over the Past 10 Years
Min: 7.79 Med: 27.64 Max: 63.66
Current: 16.46
During the past 5 years, Veritas In Silico's highest Current Ratio was 63.66. The lowest was 7.79. And the median was 27.64.
TSE:130A's Current Ratio is ranked better than 89.43% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs TSE:130A: 16.46
Veritas In Silico (TSE:130A) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Veritas In Silico Current Ratio Related Terms
Veritas In Silico Current Ratio Historical Data
* Premium members only.
The historical data trend for Veritas In Silico's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:130A vs VRTX, REGN, MRNA: Current Ratio Comparison
For the Biotechnology subindustry, Veritas In Silico's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veritas In Silico Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veritas In Silico's Current Ratio distribution charts can be found below:
* The bar in red indicates where Veritas In Silico's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veritas In Silico (TSE:130A) has a Current Ratio of 16.46 as of Jun. 2026. This is 40% below median its historical median of 27.64. Over the past decade, Veritas In Silico's Current Ratio has ranged from 7.79 to 63.66. According to the industry distribution chart, Veritas In Silico ranks #149 out of 1409 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Veritas In Silico's Current Ratio too high?
Veritas In Silico's current Current Ratio of 16.46 is 40% below median its 10-year median of 27.64. Over the past 10 years, this metric has ranged from a low of 7.79 to a high of 63.66. The Biotechnology industry median Current Ratio is 3.89. Veritas In Silico's value of 16.46 is 323.1% above this industry median. Based on the distribution chart, Veritas In Silico ranks #149 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Veritas In Silico has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Veritas In Silico ranks #149 out of 1409 companies for Current Ratio. This places Veritas In Silico in the top 11% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Veritas In Silico's value of 16.46 is 323.1% above this benchmark. Historically, Veritas In Silico's own Current Ratio has ranged from 7.79 to 63.66 over the past decade. While the company's 10-year median is 27.64 vs. the industry median of 3.89, Veritas In Silico has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veritas In Silico's current Current Ratio of 16.46 is 323.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veritas In Silico's current Current Ratio is 16.46, which is 40% below median its own 10-year median of 27.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Based on GuruFocus' analysis, Veritas In Silico (TSE:130A) is currently considered Significantly Overvalued. The stock's GF Value™ is 円266.95, compared to a current price of 円433.00 — trading 62.2% above its estimated fair value. The current Current Ratio is 16.46, which is 40% below median its 10-year median of 27.64 and 323.1% above the Biotechnology industry median of 3.89. Veritas In Silico's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Current Ratio is 16.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veritas In Silico (TSE:130A) Overvalued in 2026?
Based on GuruFocus' analysis, Veritas In Silico stock appears to be overvalued.
The current stock price of 円433.00 is trading 62.2% above its estimated GF Value™ of 円266.95.
GuruFocus considers Veritas In Silico to be Significantly Overvalued.
Key valuation signals for TSE:130A:
Current Ratio: 16.46 (40% below median its 10-year median of 27.64)
GF Value™: 円266.95 vs. price of 円433.00 (62.2% above fair value)
Industry Position: 323.1% above the Biotechnology median (#149 of 1409)
No single metric tells the full story. See the TSE:130A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
28GF Score
Get the complete analysis for TSE:130A
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:130A has been successfully added to your 
